In a challenge to Johnson & Johnson (JNJ), a federal court ruled that a patent on a key drug — the big-selling Zytiga prostate cancer treatment — is invalid, triggering the likely arrival of lower-cost generic competition, possibly in a matter of days.

The Friday decision had largely been expected by Wall Street analysts, who noted that a U.S. Patent and Trademark Office review board earlier this year had invalidated the same patent after determining it was not sufficiently inventive. The patent, which is due to expire in 2027, covered a method for administering the drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy